Consider This Before Taking a Position in PFE

Shares of Health Care sector company Pfizer moved -0.2% today, and are now trading at a price of $35.55. The large-cap stock's daily volume was 2,836,411 compared to its average volume of 26,285,181. The S&P 500 index returned a 0.0% performance.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company is based in New York and has 83,000 full time employees. Its market capitalization is $200,718,991,360. Pfizer currently offers its equity investors a dividend that yields 4.5% per year.

21 analysts are following Pfizer and have set target prices ranging from $35.0 to $75.0 per share. On average, they have given the company a rating of buy. At today's prices, PFE is trading -23.09% away from its average analyst target price of $46.23 per share.

The stock's 52 week high is $54.93 per share and its 52 week low is $35.35. With average free cash flows of $19.38 Billion that have been growing at an average rate of 27.0% over the last 4 years, Pfizer declining stock performance may not be reflective of the quality of its underlying business.

Date Reported Cash Flow from Operations ($ k) Capital expenditures ($ k) Free Cashflow ($ k) YoY Growth (%)
2022-12-31 29,267,000 -3,236,000 26,031,000 -12.85
2021-12-31 32,580,000 -2,711,000 29,869,000 157.23
2020-12-31 14,403,000 -2,791,000 11,612,000 16.19
2019-12-31 12,588,000 -2,594,000 9,994,000 n/a
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.